Taysha Gene Therapies develops gene therapies for severe brain disorders, with its lead candidate aimed at Rett syndrome. TSHA reports earnings on Tue, Nov 3, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Jul 21 | Goldman Sachs | Maintained | Buy | |
| Jun 30 | Needham | Maintained | Buy | |
| Jun 30 | Baird | Maintained | Buy | |
| Jun 23 | BMO Capital | Maintained | Buy | |
| Jun 23 | B of A Securities | Maintained | Buy |
Seasonality
How TSHA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in TSHA in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TSHA is in one of them and how their past TSHA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered TSHA in an article yet. Here's the latest on the wider market.
About Taysha Gene Therapies
Taysha Gene Therapies is a biotechnology company based in Dallas, Texas, that develops gene therapies for severe diseases of the central nervous system. Its lead candidate, TSHA-102, is being tested for Rett syndrome, a genetic disorder that mainly affects girls and causes loss of speech, hand use and motor skills. The treatment is still in clinical trials, and its intended users are patients with Rett syndrome and their caregivers.
- Headquarters
- Dallas, TX